Key facts
- A White House official told the Guardian the administration dropped Overton's FDA nomination.
- Overton needed all 12 Republican votes on the Senate health committee, where Democrats hold 11 seats.
- Cassidy had called Overton's support for breaking up combination vaccines, including MMR, almost disqualifying.
- Overton wrote in a 2023 America First Policy Institute brief that Congress should strictly regulate mifepristone.
The White House has dropped its nomination of Heidi Overton to lead the Food and Drug Administration, a White House official told the Guardian. Donald Trump nominated Overton, a physician and prominent abortion opponent, in August.
Overton has spent most of her professional career working directly for Trump or conservative groups aligned with his agenda. Her August nomination was seen as a move to bring a stabilizing Trump loyalist to the agency after a tumultuous year under Trump's first FDA commissioner, Marty Makary.
Overton faced bipartisan questions in the Senate about her willingness to break from Trump, particularly on his unsupported claims about the dangers of childhood vaccines. Republican senator Bill Cassidy, a Louisiana doctor who chairs the Senate health committee, said earlier on November 17 that he remained undecided ahead of a Senate health, labor and pensions committee vote scheduled for November 18.
Cassidy had previously called Overton's support for Trump's plan to break up combination vaccines, including the measles, mumps and rubella shot, almost disqualifying. He pressed her during a September hearing about her scientific independence and willingness to push back against Trump and health secretary Robert F Kennedy Jr, a longtime vaccine critic.
Mini Timmaraju, president and CEO of Reproductive Freedom for All, formerly Naral Pro-Choice America, said: "Heidi Overton posed a serious threat to the future of medication abortion access. Voters rejected that anti-abortion agenda nationwide, and our members kept the pressure on to tank her confirmation."
As FDA head, Overton would have overseen the agency that regulates medication abortions. In a 2023 policy brief for the conservative America First Policy Institute, she said Congress should strictly regulate the abortion pill mifepristone "to protect women and children", criticized federal policies allowing the mailing of abortion pills and wrote that abortion "is corrosive to children, women, and society broadly".
To win confirmation, Overton would have needed the votes of all 12 Republicans on the Senate health, education, labor and pensions committee, where Democrats hold 11 seats. Without committee support, she faced little chance of a full Senate vote. Republicans are racing to confirm Trump's current nominees before handing power to Senate Democrats in January.